<DOC>
	<DOC>NCT00718939</DOC>
	<brief_summary>The CVRx® Rheos® Diastolic Heart Failure Trial is a prospective, randomized, double blind trial with up to 60 subjects conducted at up to five centers in Europe. All subjects will be followed up to one year post implant.</brief_summary>
	<brief_title>Rheos® Diastolic Heart Failure Trial</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure, Diastolic</mesh_term>
	<criteria>Be at least 21 years of age. Have bilateral carotid bifurcations that are below the level of the mandible. Have a left ventricular ejection fraction ≥ 45%. Clinical Heart Failure with elevated BNP or NTProBNP. History of or suspected baroreflex failure or autonomic neuropathy. History of symptomatic bradyarrhythmias, pericardial constriction, infiltrative cardiomyopathy, cardiac valvular disease. Organ or hematologic transplant. History of prior surgery, radiation, or stent placement in carotid sinus region. History of severe chronic kidney disease. Life expectancy to less than one year.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Diastolic Heart Failure</keyword>
	<keyword>Cardiac dysfunction</keyword>
	<keyword>Heart Failure</keyword>
</DOC>